العربية
Deutsch
Français
Italiano
Español
Ελληνικά
Türkçe
Srpski
中文
+38 068 889 89 89
00380689869898 (汉语)
00380930552240
 |
00380930552240 (باللغة العربية) |
+38 044 223 28 95
Our licences
Experience of EmCell Clinic in ALS treatment
We have analyzed the experience of treating 62 ALS patients at EmCell clinic. Treatment course comprised of administration of 4 cell suspensions containing mesenchymal, ectodermal and endodermal fetal stem cells harvested from the legally aborted embryos of 4–8 weeks of gestation. The number of stem cells in the suspensions equaled 0.1–100x105/ml, the volume of the administered suspension being 0,5–4 ml. In the tables below the groups of patients and main post-treatment effects are presented
Classification of ALS patients treated with fetal stem cells by clinical forms
Classification of ALS patients treated with fetal stem cells by duration of the disease
Syndrome of the early post-transplant improvements in ALS patients treated with fetal stem cells
Main symptoms of bulbar ALS in post-transplant period
Main symptoms of classical ALS in post-transplant period
ALS progress in patients treated with fetal stem cells
Classification of ALS patients treated with fetal stem cells by clinical forms
| The number of patients | % | ||
| 1. | Classical ALS (involvement of upper and lower motor neurons) | 30 | 49 |
| 2. | Primary lateral sclerosis (involvement of upper motor neurons only) | 2 | 3 |
| 3. | Progressive bulbar palsy (degeneration of lower motor neurons: dysarthria, dysphonia, affected chewing and swallowing) | 12 | 19 |
| 4. | Progressive muscular atrophy (degeneration of lower motor neurons) | 4 | 7 |
| Combined form (1+3) - 5; (4+3) - 2 | 7 | 11 | |
| Family ALS | 7 | 11 | |
Combination with other autoimmune diseases:
|
5 1 1 1 |
||
| Total | 62 | 100 | |
Classification of ALS patients treated with fetal stem cells by duration of the disease
| Duration | The number of patients | % |
| Less than 1 year | 10 | 16 |
| Less than 2 years | 19 | 31 |
| Less than 3 years | 29 | 47 |
| More than 3 years | 4 | 6 |
| Total | 62 | 100 |
After the stem cell therapy, 42 patients (67%) reported early post-treatment improvements lasting for 1 to 4 weeks. 27 patients (44%) reported clear end of this period, the main criterion being emotional.
Syndrome of the early post-treatment improvements in ALS patients treated with fetal stem cells
| Clinical symptoms | The number of patients | % |
| Decreased weakness | 33 | 54 |
| Reduced fasciculatory activity | 25 | 41 |
| Decreased manifestations of depression | 21 | 34 |
| Improved sleep formula | 20 | 32 |
| Reduced spasticity | 17 | 27 |
| Improved appetites | 16 | 26 |
Main symptoms of bulbar ALS in post-treatment period
Note: 0 – absent; 1 – slight; beginning; 2 – expressed; evident; definite; 3 – markedly expressed, no function
| Duration of treatment/The number of patients (19) | ||||||||||||||||||||||||||||||||
| Less than 1 year (4) | Less than 2 years (6) | Less than 3 years (8) | Over 3 years (1) | |||||||||||||||||||||||||||||
| Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment | After the treatment | |||||||||||||||||||||||||
| 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | |
| Dysarthria | 1 | 2 | 1 | 2 | 2 | 2 | 4 | 5 | 1 | 6 | 2 | 2 | 4 | 2 | 1 | 1 | ||||||||||||||||
| Dysphonia | 1 | 2 | 1 | 2 | 2 | 2 | 4 | 5 | 1 | 6 | 2 | 1 | 5 | 2 | 1 | 1 | ||||||||||||||||
| Dysprosody | 1 | 2 | 1 | 2 | 2 | 2 | 4 | 3 | 3 | 6 | 2 | 1 | 5 | 2 | 1 | 1 | ||||||||||||||||
| Fasciculations on the tongue | 2 | 2 | 1 | 3 | 3 | 3 | 4 | 2 | 1 | 6 | 1 | 7 | 1 | 1 | 1 | |||||||||||||||||
| Tongue atrophy | 3 | 1 | 1 | 2 | 1 | 1 | 5 | 1 | 5 | 6 | 2 | 5 | 3 | 1 | 1 | |||||||||||||||||
| Chewing dysfunction | 3 | 1 | 4 | 4 | 2 | 5 | 1 | 5 | 2 | 1 | 4 | 2 | 2 | 1 | 1 | |||||||||||||||||
| Dysphagia | 3 | 1 | 4 | 3 | 2 | 1 | 4 | 2 | 3 | 4 | 1 | 4 | 3 | 1 | 1 | 1 | ||||||||||||||||
| Regurgitation of liquid food | 4 | 4 | 4 | 2 | 5 | 1 | 1 | 7 | 2 | 6 | 1 | 1 | ||||||||||||||||||||
| Hypersalivation | 3 | 1 | 4 | 2 | 1 | 3 | 4 | 2 | 2 | 4 | 2 | 2 | 6 | 1 | 1 | |||||||||||||||||
Main symptoms of classical ALS in post-treatment period
Note: 0 – absent; 1 – slight; beginning; 2 – expressed; evident; definite; 3 – markedly expressed, no function
|
Duration of treatment/The number of patients (35)
|
||||||||||||||||||||||||||||||||
| Less than 1 year (6) | Less than 2 years (11) | Less than 3 years (15) | Over 3 years (3) | |||||||||||||||||||||||||||||
| Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment | After the treatment | Before the treatment | After the treatment | |||||||||||||||||||||||||
| 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | |
| Fasciculations | 4 | 2 | 1 | 5 | 1 | 3 | 7 | 1 | 6 | 4 | 7 | 8 | 8 | 7 | 1 | 2 | 1 | 2 | ||||||||||||||
| Atrophy of UE | 1 | 3 | 2 | 1 | 4 | 1 | 2 | 5 | 4 | 3 | 4 | 4 | 1 | 4 | 10 | 1 | 4 | 10 | 1 | 2 | 1 | 2 | ||||||||||
| Wrist Atrophy | 4 | 2 | 1 | 5 | 2 | 5 | 4 | 3 | 5 | 3 | 2 | 2 | 11 | 3 | 1 | 11 | 1 | 2 | 1 | 2 | ||||||||||||
| Atrophy of LE | 3 | 3 | 3 | 3 | 1 | 6 | 4 | 2 | 5 | 4 | 1 | 6 | 8 | 1 | 6 | 8 | ||||||||||||||||
| ROM in the wrists | 1 | 3 | 2 | 2 | 4 | 4 | 5 | 2 | 5 | 3 | 3 | 1 | 4 | 10 | 2 | 4 | 9 | 1 | 2 | 1 | 2 | |||||||||||
| ROM in UE | 3 | 3 | 5 | 1 | 4 | 4 | 3 | 7 | 1 | 3 | 2 | 2 | 11 | 2 | 2 | 11 | 1 | 2 | 1 | 2 | ||||||||||||
| ROM in LE | 2 | 2 | 2 | 3 | 3 | 2 | 5 | 4 | 4 | 3 | 4 | 1 | 6 | 8 | 1 | 6 | 8 | 2 | 1 | 1 | 1 | 1 | ||||||||||
| Quality of the gait | 2 | 2 | 2 | 3 | 3 | 2 | 5 | 4 | 4 | 3 | 4 | 1 | 6 | 8 | 2 | 5 | 8 | 2 | 1 | 2 | 1 | |||||||||||
| Spastic paresis of UE | 5 | 1 | 6 | 5 | 4 | 2 | 6 | 1 | 3 | 1 | 10 | 2 | 2 | 10 | 1 | 2 | 1 | 2 | 1 | 2 | 1 | |||||||||||
| Spastic paresis of LE | 3 | 3 | 2 | 4 | 2 | 3 | 3 | 3 | 2 | 4 | 4 | 1 | 2 | 8 | 5 | 2 | 2 | 8 | 3 | 3 | 1 | 2 | ||||||||||
| Weakness | 2 | 4 | 4 | 2 | 2 | 5 | 4 | 4 | 4 | 1 | 2 | 4 | 9 | 3 | 5 | 6 | 2 | 1 | 1 | 1 | 1 | |||||||||||
ALS progress in patients treated with fetal stem cells
| After the treatment | 4 months | 5 months | 6 months | 12 months |
| The number of patients | 27% | 42% | 58% | 83% |
| Tweet |
| Fetal stem cells treatment results depend on: disease's severity, age of the patient, adherence for the medications and regime. Treatment results, presented on this site, are individual for each clinical case. |
.png "wechat")
.png "wechat")
.png "wechat")